Genetron Health Completes Privatization Process

Genetron Holdings Ltd (GTH) has released an update.

Genetron Holdings Limited, a leader in China’s precision oncology sector, has completed its transition to a privately held company following a merger with Genetron New Co Limited, with shareholders receiving $0.272 in cash per ordinary share and $4.08 per American depositary share. As a result, the company will delist from Nasdaq, ceasing to be publicly traded, and intends to suspend its SEC reporting obligations. Shareholders are advised to await further instructions before surrendering shares for the merger consideration.

For further insights into GTH stock, check out TipRanks’ Stock Analysis page.